Lantheus (LNTH) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Oct. 28, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36569
Entity Registrant Name	LANTHEUS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2318913
Entity Address, Address Line One	331 Treble Cove Road
Entity Address, Postal Zip Code	01862
Entity Address, City or Town	North Billerica,
Entity Address, State or Province	MA
City Area Code	(978)
Local Phone Number	671-8001
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	LNTH
Security Exchange Name	NASDAQ
Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		67,690,586
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001521036
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 91,475	$ 79,612
Accounts receivable, net	64,054	54,002
Inventory	33,949	35,744
Other current assets	12,043	9,625
Assets held for sale	0	5,242
Total current assets	201,521	184,225
Property, plant and equipment, net	116,441	120,171
Intangibles, net	356,883	376,012
Goodwill	61,189	58,632
Deferred tax assets, net	66,493	70,147
Other long-term assets	45,289	60,634
Total assets	847,816	869,821
Current liabilities
Current portion of long-term debt and other borrowings	10,356	20,701
Accounts payable	20,508	16,284
Accrued expenses and other liabilities	46,039	41,726
Liabilities held for sale	0	1,793
Total current liabilities	76,903	80,504
Asset retirement obligations	15,185	14,020
Long-term debt, net and other borrowings	166,741	197,699
Other long-term liabilities	89,643	63,393
Total liabilities	348,472	355,616
Commitments and contingencies (See Note 19)
Stockholders’ equity
Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding)	0	0
Common stock ($0.01 par value, 250,000 shares authorized; 67,659 and 66,875 shares issued and outstanding, respectively)	677	669
Additional paid-in capital	680,819	665,530
Accumulated deficit	(181,010)	(149,946)
Accumulated other comprehensive loss	(1,142)	(2,048)
Total stockholders’ equity	499,344	514,205
Total liabilities and stockholders’ equity	$ 847,816	$ 869,821

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	67,659,000	66,875,000
Common stock, shares outstanding (in shares)	67,659,000	66,875,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 102,073	$ 88,544	$ 295,646	$ 245,258
Cost of goods sold	59,404	52,284	165,859	145,148
Gross profit	42,669	36,260	129,787	100,110
Operating expenses
Sales and marketing	17,195	11,609	48,999	28,044
General and administrative	28,550	18,217	87,865	55,586
Research and development	11,252	11,684	33,673	20,150
Total operating expenses	56,997	41,510	170,537	103,780
Gain on sale of assets	0	0	15,263	0
Operating loss	(14,328)	(5,250)	(25,487)	(3,670)
Interest expense	1,569	2,808	6,224	6,668
Gain on extinguishment of debt	0	0	(889)	0
Other loss (income)	3,940	(596)	3,209	(1,702)
Loss before income taxes	(19,837)	(7,462)	(34,031)	(8,636)
Income tax (benefit) expense	(6,422)	(1,076)	(2,967)	1,425
Net loss	$ (13,415)	$ (6,386)	$ (31,064)	$ (10,061)
Net loss per common share:
Basic (in dollars per share)	$ (0.20)	$ (0.10)	$ (0.46)	$ (0.20)
Diluted (in dollars per share)	$ (0.20)	$ (0.10)	$ (0.46)	$ (0.20)
Weighted-average common shares outstanding:
Basic (in shares)	67,623	66,820	67,409	49,858
Diluted (in shares)	67,623	66,820	67,409	49,858

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,415)	$ (6,386)	$ (31,064)	$ (10,061)
Other comprehensive (loss) income:
Foreign currency translation	(240)	185	55	(9)
Unrealized gain (loss) on cash flow hedges, net of tax	98	(89)	851	(1,541)
Total other comprehensive (loss) income	(142)	96	906	(1,550)
Comprehensive loss	$ (13,557)	$ (6,290)	$ (30,158)	$ (11,611)

Condensed Consolidated Changes

Condensed Consolidated Changes In Stockholders' Equity (Statement) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		39,251
Beginning balance at Dec. 31, 2019	$ 114,601	$ 393	$ 251,641	$ (136,473)	$ (960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	3,337			3,337
Other comprehensive income (loss)	(1,434)				(1,434)
Stock option exercises and employee stock plan purchases (in shares)		33
Stock option exercises and employee stock plan purchases	366		366
Vesting of restricted stock awards and units (in shares)		563
Vesting of restricted stock awards and units	0	$ 6	(6)
Shares withheld to cover taxes (in shares)		(97)
Shares withheld to cover taxes	(1,547)	$ (1)	(1,546)
Stock-based compensation	3,075		3,075
Ending balance (in shares) at Mar. 31, 2020		39,750
Ending balance at Mar. 31, 2020	118,398	$ 398	253,530	(133,136)	(2,394)
Beginning balance (in shares) at Dec. 31, 2019		39,251
Beginning balance at Dec. 31, 2019	114,601	$ 393	251,641	(136,473)	(960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(10,061)
Other comprehensive income (loss)	(1,550)
Ending balance (in shares) at Sep. 30, 2020		66,850
Ending balance at Sep. 30, 2020	513,579	$ 668	661,955	(146,534)	(2,510)
Beginning balance (in shares) at Mar. 31, 2020		39,750
Beginning balance at Mar. 31, 2020	118,398	$ 398	253,530	(133,136)	(2,394)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(7,012)			(7,012)
Other comprehensive income (loss)	(212)				(212)
Stock option exercises and employee stock plan purchases (in shares)		7
Stock option exercises and employee stock plan purchases	50		50
Vesting of restricted stock awards and units (in shares)		242
Vesting of restricted stock awards and units	0	$ 2	(2)
Shares withheld to cover taxes (in shares)		(36)
Shares withheld to cover taxes	(485)	$ (1)	(484)
Issuance of common stock (in shares)		26,845
Issuance of common stock, net of $3,776 issuance costs	394,334	$ 269	394,065
Fair value of replacement options related to pre-acquisition services	7,125		7,125
Stock-based compensation	3,385		3,385
Ending balance (in shares) at Jun. 30, 2020		66,808
Ending balance at Jun. 30, 2020	515,583	$ 668	657,669	(140,148)	(2,606)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(6,386)			(6,386)
Other comprehensive income (loss)	96				96
Stock option exercises and employee stock plan purchases (in shares)		32
Stock option exercises and employee stock plan purchases	344		344
Vesting of restricted stock awards and units (in shares)		13
Vesting of restricted stock awards and units	0	$ 1	(1)
Shares withheld to cover taxes (in shares)		(3)
Shares withheld to cover taxes	(50)	$ (1)	(49)
Stock-based compensation	3,992		3,992
Ending balance (in shares) at Sep. 30, 2020		66,850
Ending balance at Sep. 30, 2020	513,579	$ 668	661,955	(146,534)	(2,510)
Beginning balance (in shares) at Dec. 31, 2020		66,875
Beginning balance at Dec. 31, 2020	514,205	$ 669	665,530	(149,946)	(2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	9,008			9,008
Other comprehensive income (loss)	808				808
Stock option exercises and employee stock plan purchases (in shares)		155
Stock option exercises and employee stock plan purchases	2,380	$ 1	2,379
Vesting of restricted stock awards and units (in shares)		489
Vesting of restricted stock awards and units	0	$ 5	(5)
Shares withheld to cover taxes (in shares)		(85)
Shares withheld to cover taxes	(1,599)	$ (1)	(1,598)
Stock-based compensation	3,317		3,317
Ending balance (in shares) at Mar. 31, 2021		67,434
Ending balance at Mar. 31, 2021	528,119	$ 674	669,623	(140,938)	(1,240)
Beginning balance (in shares) at Dec. 31, 2020		66,875
Beginning balance at Dec. 31, 2020	514,205	$ 669	665,530	(149,946)	(2,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(31,064)
Other comprehensive income (loss)	906
Ending balance (in shares) at Sep. 30, 2021		67,659
Ending balance at Sep. 30, 2021	499,344	$ 677	680,819	(181,010)	(1,142)
Beginning balance (in shares) at Mar. 31, 2021		67,434
Beginning balance at Mar. 31, 2021	528,119	$ 674	669,623	(140,938)	(1,240)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(26,657)			(26,657)
Other comprehensive income (loss)	240				240
Stock option exercises and employee stock plan purchases (in shares)		116
Stock option exercises and employee stock plan purchases	2,043	$ 1	2,042
Vesting of restricted stock awards and units (in shares)		51
Vesting of restricted stock awards and units	0	$ 1	(1)
Shares withheld to cover taxes (in shares)		(9)
Shares withheld to cover taxes	(193)		(193)
Stock-based compensation	4,588		4,588
Ending balance (in shares) at Jun. 30, 2021		67,592
Ending balance at Jun. 30, 2021	508,140	$ 676	676,059	(167,595)	(1,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(13,415)			(13,415)
Other comprehensive income (loss)	(142)				(142)
Stock option exercises and employee stock plan purchases (in shares)		48
Stock option exercises and employee stock plan purchases	961	$ 1	960
Vesting of restricted stock awards and units (in shares)		23
Shares withheld to cover taxes (in shares)		(4)
Shares withheld to cover taxes	(67)		(67)
Stock-based compensation	3,867		3,867
Ending balance (in shares) at Sep. 30, 2021		67,659
Ending balance at Sep. 30, 2021	$ 499,344	$ 677	$ 680,819	$ (181,010)	$ (1,142)

Condensed Consolidated Change_2

Condensed Consolidated Changes In Stockholders' Equity (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 3,776

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (31,064)	$ (10,061)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation, amortization and accretion	30,088	16,295
Impairment of long-lived assets	9,540	7,275
Amortization of debt related costs	430	199
Changes in fair value of contingent assets and liabilities	28,500	800
Gain on extinguishment of debt	(889)	0
Provision for excess and obsolete inventory	2,317	1,870
Stock-based compensation	11,772	10,452
Gain on sale of assets	(15,263)	0
Deferred taxes	1,028	(781)
Long-term income tax receivable	3,092	(1,664)
Long-term income tax payable and other long-term liabilities	(3,617)	2,114
Other	1,724	1,034
(Decreases) increases in cash from operating assets and liabilities:
Accounts receivable	(7,721)	(703)
Inventory	(625)	(9,593)
Other current assets	1,998	1,563
Accounts payable	4,776	3,762
Accrued expenses and other liabilities	3,941	(6,735)
Net cash provided by operating activities	40,027	15,827
Investing activities
Capital expenditures	(7,596)	(8,689)
Proceeds from sale of assets, net	15,823	0
Lending on bridge loan	0	(10,000)
Cash acquired in acquisition of business	0	17,562
Net cash provided by (used in) investing activities	8,227	(1,127)
Financing activities
Payments on long-term debt and other borrowings	(40,757)	(11,166)
Equity issuance costs	0	(3,777)
Deferred financing costs	0	(1,223)
Proceeds from stock option exercises	4,616	77
Proceeds from issuance of common stock	768	683
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(1,859)	(2,082)
Net cash used in financing activities	(37,232)	(17,488)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash	(99)	4
Net increase (decrease) in cash, cash equivalents and restricted cash	10,923	(2,784)
Cash, cash equivalents and restricted cash, beginning of period	82,694	92,919
Cash, cash equivalents and restricted cash, end of period	93,617	90,135
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	91,475	87,994
Restricted cash included in other long-term assets	2,142	2,141
Cash, cash equivalents and restricted cash at end of period	$ 93,617	$ 90,135

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ended December 31, 2021 or any future period. In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, which resulted in a change in operating segments. Please refer to Note 20, “Segment Information”, for further details. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities Exchange Commission (“SEC”) on February 25, 2021. Progenics Acquisition On June 19, 2020 (the “Closing Date”), pursuant to the Amended and Restated Agreement and Plan of Merger, dated as of February 20, 2020 (the “Merger Agreement”), by and among Holdings, Plato Merger Sub, Inc., a wholly-owned subsidiary of Holdings (“Merger Sub”), and Progenics, Holdings completed the previously announced acquisition of Progenics by means of a merger of Merger Sub with and into Progenics, with Progenics surviving such merger as a wholly-owned subsidiary of Holdings (the “Progenics Acquisition”). In accordance with the Merger Agreement, at the effective time of the Progenics Acquisition (the “Effective Time”), each share of Progenics common stock, par value $0.0013 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Progenics common stock owned by Holdings, Progenics or any of their wholly-owned subsidiaries) was automatically cancelled and converted into the right to receive (i) 0.31 (the “Exchange Ratio”) of a share of Holdings common stock, par value $0.01 per share, and (ii) one contingent value right (a “CVR”) tied to the financial performance of PyL (18F-DCFPyL), Progenics’ prostate-specific membrane antigen (“PSMA”) targeted imaging agent designed to visualize prostate cancer. This agent was approved by the U.S. Food and Drug Administration (“FDA”) on May 26, 2021 under the name PYLARIFY (piflufolastat F 18), and the commercial launch of this agent has begun. Each CVR will entitle its holder to receive a pro rata share of aggregate cash payments equal to 40% of U.S. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100.0 million and $150.0 million, respectively. In no event will the Company’s aggregate payments in respect of the CVRs, together with any other non-stock consideration treated as paid in connection with the Progenics Acquisition, exceed 19.9% of the total consideration the Company pays in the Progenics Acquisition (which the Company estimates could be approximately $100.0 million). No fractional shares of Holdings common stock were issued in the Progenics Acquisition, and Progenics’ former stockholders have received cash in lieu of any fractional shares of Holdings common stock. As a result of the acquisition, Holdings issued 26,844,877 shares of Holdings common stock and 86,630,633 CVRs to former Progenics stockholders. Please refer to Note 8, “Business Combinations”, for further details on the acquisition. COVID-19 The Company experienced operational and financial impacts from the COVID-19 pandemic beginning late in the first quarter of 2020 and through the date of this filing, including the impact of stay-at-home mandates and advisories, and a decline in the volume of certain procedures and treatments using the Company’s products. For example, there has been a substantial reduction in pulmonary ventilation studies in which the Company’s product, Xenon, is used. As a result of the COVID-19 pandemic, the Company undertook a thorough analysis of all its discretionary expenses. In the first quarter of 2020, the Company implemented certain cost reduction initiatives. For most of the second quarter of 2020, the Company reduced the Company’s work week from five days to four days and reduced the pay for employees by varying amounts depending on level of seniority. During the second quarter of 2020, Progenics also implemented certain cost reduction initiatives and paused new enrollment in the ARROW Phase 2 study of 1095, a PSMA-targeted therapeutic, in metastatic castrate-resistant prostate cancer (“mCRPC”) patients to minimize the risk to subjects and healthcare providers during the pandemic. New enrollment in that study restarted in October 2020. GE Healthcare Limited (“GE Healthcare”), the Company’s development and commercialization partner for flurpiridaz fluorine-18 (“F 18”), also delayed enrollment in the second Phase 3 clinical trial of flurpiridaz F 18 because of the pandemic and resumed enrollment in the third quarter of 2020. Although some of the restrictions, including stay-at-home mandates, imposed in response to the COVID-19 pandemic have been lifted in much of the United States (the “U.S.”), and there has been a rapid rollout and development of certain vaccines, the resurgence of COVID-19 infections did impact certain aspects of the Company’s business during the third quarter of 2021 and the pandemic could still have a future negative impact on the Company's business, particularly if there are additional resurgences as a result of mutations or other variations to the virus that increase its communicability or its impact on certain populations, geographic regions and the healthcare system, including elective procedures and hospital access. While the impact of COVID-19 on the Company’s results of operations and cash flows has been material, given continued uncertainty about the future trajectory of the pandemic, the Company remains unable to accurately predict the impact of COVID-19 on its overall 2021 operations and financial results or cash flows and whether the on-going impact of COVID-19 could lead to potential future impairments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Reclassifications Certain immaterial reclassifications in the prior period condensed consolidated statements of cash flows have been reclassified to conform to the current year period financial statement presentation. Reclassifications include $0.2 million from provision for bad debt to other at September 30, 2020. The Company had a reclassification in presentation related to rebates and allowances within product revenue. Please refer to Note 3, “Revenue from Contracts with Customers” for further details. Recent Accounting Pronouncements Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Nine Months Ended September 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers The following table summarizes revenue by revenue source as follows: Three Months Ended Nine Months Ended Major Products/Service Lines (in thousands) 2021 2020 2021 2020 Product revenue, net (1) $ 96,678 $ 83,661 $ 277,559 $ 238,801 License and royalty revenues 5,395 4,883 18,087 6,457 Total revenues $ 102,073 $ 88,544 $ 295,646 $ 245,258 ________________________________ (1) The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other includes partnerships related to other products of the Company, such as RELISTOR. Revenue by product category on a net basis is as follows: Three Months Ended Nine Months Ended (in thousands) 2021 2020 (1) 2021 2020 (1) DEFINITY $ 57,636 $ 50,359 $ 173,448 $ 139,989 TechneLite 22,680 21,113 69,252 62,560 Other precision diagnostics 7,563 8,585 21,289 28,782 Total precision diagnostics 87,879 80,057 263,989 231,331 Radiopharmaceutical oncology 8,890 3,323 13,203 7,474 Strategic partnerships and other 5,304 5,164 18,454 6,453 Total revenues $ 102,073 $ 88,544 $ 295,646 $ 245,258 ________________________________ (1) The Company reclassified rebates and allowances of $5.5 million and $13.8 million within each product category, which included $5.1 million and $12.6 million for DEFINITY, $0.3 million and $0.9 million for TechneLite and $0.1 million and $0.2 million for other precision diagnostics, for the three and nine months ended September 30, 2020, respectively. The Company’s performance obligations are typically part of contracts that have an original expected duration of one year or less. As such, the Company is not disclosing the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied (or partially satisfied) as of the end of the reporting period.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability of fair value measurements, financial instruments are categorized based on a hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1 — Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 — Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.) and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). • Level 3 — Unobservable inputs that reflect a Company’s estimates about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including its own data. The Company’s financial assets and liabilities measured at fair value on a recurring basis consist of money market funds, interest rate swaps, a contingent receivable and contingent consideration liabilities. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. The fair value of the interest rate swaps is determined based on observable market-based inputs, including interest rate curves and reflects the contractual terms of these instruments, including the period to maturity. Please refer to Note 13, “Derivative Instruments”, for further details on the interest rate swaps. The Company recorded a contingent receivable and the contingent consideration liabilities resulting from the Progenics Acquisition at fair value based on inputs that are not observable in the market. Please refer to Note 8, “Business Combinations”, for further details on the acquisition. The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 39,141 $ 39,141 $ — $ — Contingent receivable 13,800 — — 13,800 Total assets $ 52,941 $ 39,141 $ — $ 13,800 Liabilities: Interest rate swaps $ 766 $ — $ 766 $ — Contingent consideration liabilities 46,800 — — 46,800 Total liabilities $ 47,566 $ — $ 766 $ 46,800 December 31, 2020 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 35,457 $ 35,457 $ — $ — Contingent receivable 11,300 — — 11,300 Total assets $ 46,757 $ 35,457 $ — $ 11,300 Liabilities: Interest rate swaps $ 1,908 $ — $ 1,908 $ — Contingent consideration liabilities 15,800 — — 15,800 Total liabilities $ 17,708 $ — $ 1,908 $ 15,800 During the three and nine months ended September 30, 2021, there were no transfers into or out of Level 3. As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics from CytoDyn Inc. related to a prior sale of certain intellectual property. The Company has the right to receive $5.0 million upon regulatory approval and a 5% royalty on net sales of approved products. The Company considers the contingent receivable a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flows that included significant estimates and assumptions pertaining to regulatory events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success. As part of the Progenics Acquisition, the Company issued CVRs and recorded the fair value as part of consideration transferred. Refer to Note 1, “Basis of Presentation” for further details on the CVRs. Additionally, the Company assumed contingent consideration liabilities related to a previous acquisition completed by Progenics in 2013 (“2013 Acquisition”). These contingent consideration liabilities include potential payments of up to $70.0 million if the Company attains certain net sales targets primarily for AZEDRA and 1095 and a $5.0 million 1095 commercialization milestone. Additionally, there is a potential payment of up to $10.0 million related to a 1404 commercialization milestone. The Company’s total potential payments related to the 2013 Acquisition are approximately $85.0 million. The Company considers the contingent consideration liabilities relating to the CVRs and the 2013 Acquisition, each a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value of these was determined based on probability adjusted discounted cash flows and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving regulatory approval of the development projects and subsequent commercial success. Significant changes in any of the probabilities of success, the probabilities as to the periods in which milestones will be achieved, discount rates or underlying revenue forecasts would result in a significantly higher or lower fair value measurement. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the condensed consolidated statements of operations. The Company can give no assurance that the actual amounts paid, if any, in connection with the contingent consideration liabilities, including the CVRs, will be consistent with any recurring fair value estimate of such contingent consideration liabilities. The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at September 30, 2021. Fair Value at Assumptions (in thousands) September 30, 2021 December 31, 2020 Valuation Technique Unobservable Input September 30, 2021 December 31, 2020 Contingent receivable: Regulatory milestone $ 3,300 $ 3,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2021 Probability of success 90 % 90 % Discount rate 18 % 24 % Royalties 10,500 8,100 Probability adjusted discounted cash flow model Probability of success 13% - 77% 13% - 77% Discount rate 18 % 24 % Total $ 13,800 $ 11,300 Fair Value at Assumptions (in thousands) September 30, 2021 December 31, 2020 Valuation Technique Unobservable Input September 30, 2021 December 31, 2020 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 33,200 $ 4,200 Monte Carlo simulation Period of expected milestone achievement 2022 - 2023 2022 - 2023 Discount rate 18 % 24 % 1095 commercialization milestone 1,900 2,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 45 % Discount rate 0.9 % 0.5 % Net sales targets - AZEDRA and 1095 11,700 9,400 Monte Carlo simulation Probability of success 40% - 100% 40% - 100% Discount rate 17% - 18% 23% - 24% Total $ 46,800 $ 15,800 For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Nine Months Ended Nine Months Ended 2021 2020 2021 2020 Fair value, beginning of period $ 11,300 $ — $ 15,800 $ — Progenics acquisition — 10,100 — 16,300 Changes in fair value included in net loss 2,500 100 31,000 900 Fair value, end of period $ 13,800 $ 10,200 $ 46,800 $ 17,200 The change in fair value of the contingent financial asset and contingent financial liabilities, including the CVRs, resulted in an expense of $28.5 million for the nine months ended September 30, 2021 and was primarily due to changes in revenue forecasts, changes in market conditions, a decrease in discount rates and the passage of time.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Historically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year to “ordinary” income or loss (pretax income or loss excluding unusual or infrequently occurring discrete events). For the three- and nine-month periods ended September 30, 2021, the Company has computed its provision for income taxes under the discrete method, which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date period. We determined that since small changes in estimated “ordinary” income would result in significant changes in the estimated annual effective tax rate, the historical method would not provide a reliable estimate for the three- and nine-month periods ended September 30, 2021. The Company’s income tax expense is presented below: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Income tax (benefit) expense $ (6,422) $ (1,076) $ (2,967) $ 1,425 The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realizability of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more-likely-than-not realizable, the Company evaluated all available positive and negative evidence, and weighed the objective evidence and expected impact. The Company assessed the need for a valuation allowance against certain state tax credit carryforwards added through the Progenics Acquisition. The Company continues to record other valuation allowances of $1.2 million against the net deferred tax assets of its U.K. subsidiary, and $2.0 million against the net deferred tax assets of its Sweden subsidiary. In connection with the Company’s acquisition of the medical imaging business from Bristol-Myers Squibb (“BMS”) in 2008, the Company recorded a liability for uncertain tax positions related to the acquired business and simultaneously entered into a tax indemnification agreement with BMS under which BMS agreed to indemnify the Company for any payments made to settle those uncertain tax positions with the state taxing authorities. Accordingly, a long-term receivable is recorded to account for the expected value to the Company of future indemnification payments to be paid on behalf of the Company by BMS, net of actual tax benefits received by the Company. The tax indemnification receivable is recorded within other long-term assets. During the third quarter of 2021, the Company entered into a settlement agreement with one state and accordingly reduced the amount of the uncertain tax positions by $5.5 million. The settlement payment to that state and the tax indemnification payment from BMS will be made in the fourth quarter of 2021. The Company continues to accrue interest on the outstanding uncertain tax positions. In accordance with the Company’s accounting policy, the change in the tax liabilities, penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within income tax expense. As these reserves change (for example, by the state tax settlement noted above), adjustments are included in income tax expense while the offsetting adjustment is included in other income. Assuming that the remaining receivable from BMS continues to be considered recoverable by the Company, there will be no effect on net income and no net cash outflows related to these liabilities. In addition to the state tax settlement noted above, for the nine months ended September 30, 2021, the Company released $0.7 million of liabilities for uncertain tax positions, including interest and penalties of $0.5 million. This included a release of liabilities of $0.1 million, including interest and penalties of $0.4 million, due to a change in estimate with respect to the Company’s indemnified uncertain tax positions arising from new information obtained during the year. The remaining release of $0.2 million of liability was due to the lapse of a statute of limitations. On June 19, 2020, the Company completed the Progenics Acquisition in a transaction that is expected to qualify as a tax-deferred reorganization under Section 368 of the Internal Revenue Code. The transaction resulted in an ownership change of Progenics under Section 382 of the Internal Revenue Code and a limitation on the utilization of Progenics’ precombination tax attributes. All of Progenics’ precombination federal research and Orphan drug credits have been removed from the balance sheet, and the gross carrying value of the tax loss carryforwards reduced to their realizable value on the opening balance sheet, in accordance with the Section 382 limitation. Deferred tax liabilities arising from the purchase accounting basis step-up in identified intangibles were recorded at acquisition, resulting in an initial net overall deferred tax liability for Progenics after the application of acquisition accounting. The Company finalized the acquisition accounting for income taxes in the first quarter of 2021 resulting in a reduction of deferred tax assets, primarily related to state research credit carryforwards and an increase to goodwill of $2.6 million.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consisted of the following: (in thousands) September 30, December 31, Raw materials $ 15,173 $ 16,000 Work in process 11,560 11,212 Finished goods 7,216 8,532 Total inventory $ 33,949 $ 35,744 Inventory costs associated with products that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefit of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. As of September 30, 2021, the Company had $3.2 million of such product costs included in inventories related to DEFINITY that have been manufactured through the Company’s in-house manufacturing capabilities, which is awaiting regulatory approval.

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net, consisted of the following: (in thousands) September 30, December 31, Land $ 13,450 $ 13,450 Buildings 73,285 70,381 Machinery, equipment and fixtures 82,596 77,854 Computer software 24,223 23,644 Construction in progress 8,887 11,254 202,441 196,583 Less: accumulated depreciation and amortization (86,000) (76,412) Total property, plant and equipment, net $ 116,441 $ 120,171 Depreciation and amortization expense related to property, plant and equipment, net, was $3.6 million and $3.4 million for the three months ended September 30, 2021 and 2020, respectively, and $9.8 million and $9.1 million for the nine months ended September 30, 2021 and 2020, respectively. The Company tests long-lived assets for recoverability whenever events or changes in circumstances suggest that the carrying value of an asset or group of assets may not be recoverable. During the three months ended September 30, 2021, the Company reviewed certain facts relating to an asset group that included the right-of-use (“ROU”) asset associated with the lease of office space in the World Trade Center (the “WTC lease”) in New York City and resulted in a change to the asset group due to the negotiation of a sublease. Please refer to Note 16, “Leases” for further details. During the three months ended March 31, 2020, as a result of a decline in expected future cash flows and the effect of the COVID-19 pandemic related to certain other nuclear legacy manufacturing assets, the Company determined certain impairment triggers had occurred. Accordingly, the Company performed an undiscounted cash flow analysis as of March 31, 2020. Based on the undiscounted cash flow analysis, the Company determined that the manufacturing assets had net carrying values that exceeded their estimated undiscounted future cash flows. The Company then estimated the fair values of the asset group based on their discounted cash flows. The carrying value exceeded the fair value and as a result, the Company recorded a non-cash impairment of $7.3 million for the nine months ended September 30, 2020 in cost of goods sold in the condensed consolidated statements of operations.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations On June 19, 2020, the Company completed the Progenics Acquisition. The acquisition combined the commercialization, supply chain and manufacturing expertise of the Company with the currently commercialized products and research and development pipeline of Progenics. Progenics brought to the Company several commercial products and a pipeline of product candidates that further diversify the Company’s commercial and clinical development portfolios. Under the terms of the Merger Agreement, the Company acquired all the issued and outstanding shares of Progenics common stock for a purchase price of $419.0 million by means of an all-stock transaction, which includes options to purchase Holdings common stock (“Replacement Stock Options”) for precombination services as well as CVRs. The CVRs were accounted for as contingent consideration, the fair value of which was determined using a Monte Carlo simulation. Additionally, the fair value of the Replacement Stock Options was recorded as a component of consideration transferred. Finally, as a result of the Progenics Acquisition, Lantheus effectively settled an existing bridge loan with Progenics at the recorded amount (principal and accrued interest) of $10.1 million, representing the effective settlement of a preexisting relationship. This effective settlement of the bridge loan was treated as a component of consideration transferred. The Company determined that the bridge loan was at market terms and no gain or loss was recorded upon settlement. The acquisition date fair value of the consideration transferred in the acquisition consisted of the following: (in thousands) Amount Issuance of common stock $ 398,110 Fair value of replacement options 7,125 Fair value of bridge loan settled at close 10,074 Fair value of contingent considerations (CVRs) 3,700 Total consideration transferred (1) $ 419,009 (1) Non-cash investing and financing activities in the condensed consolidated statements of cash flows The transaction was accounted for as a business combination which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company’s results of operations. The Company recorded a measurement period adjustment of $2.6 million related to deferred taxes for the three months ended March 31, 2021, which finalized all measurement period adjustments related to the Progenics Acquisition. The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. (in thousands) Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 15,421 $ — $ 15,421 Accounts receivable 5,787 — 5,787 Inventory 915 160 1,075 Other current assets 3,250 434 3,684 Property, plant and equipment 14,972 — 14,972 Identifiable intangible assets (weighted average useful life): Currently marketed product (15 years) 142,100 800 142,900 Licenses (11.5 years) 87,500 (1,700) 85,800 Developed technology (9 years) 3,000 (600) 2,400 IPR&D 150,900 200 151,100 Other long-term assets 37,631 — 37,631 Accounts payable (1,616) — (1,616) Accrued expenses and other liabilities (8,207) (80) (8,287) Other long-term liabilities (30,778) (380) (31,158) Long-term debt and other borrowings (40,200) — (40,200) Deferred tax liabilities (3,717) (2,258) (5,975) Goodwill 42,051 3,424 45,475 Total consideration transferred $ 419,009 $ — $ 419,009 Intangible assets acquired consist of currently marketed products, licenses, developed technology and in-process research and development (“IPR&D”). The fair value of the acquired intangible assets was determined based on estimated future revenues, royalty rates and discount rates, among other variables and estimates. The acquired intangible assets subject to amortization were assigned useful lives based on the expected use of the assets and the regulatory and economic environment within which they are being used and are being amortized on a straight-line basis over the respective estimated useful lives. The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.0% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. As part of the Progenics Acquisition, the Company acquired the right to receive certain future milestone and royalty payments due to Progenics, related to a prior sale of certain intellectual property. The estimated fair value of the acquired contingent receivable of $10.1 million was determined by applying a probability adjusted discounted cash flow model based on estimated future expected payments and recorded in other long-term assets. The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Progenics’ assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $45.5 million recognized in connection with the acquisition is not deductible for tax purposes. The Company recognized $1.6 million and $10.5 million of acquisition-related costs, including legal, accounting, compensation arrangements and other related fees that were expensed when incurred in the three and nine months ended September 30, 2020, respectively. These costs are recorded in general and administrative expenses in the condensed consolidated statements of operations. Progenics Pro Forma Financial Information Progenics has been included in the Company’s consolidated financial statements since the acquisition date. Progenics contributed revenues of $5.9 million and $6.9 million, as well as a net loss of $12.6 million and $15.8 million to the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2020, respectively. The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019: Nine Months Ended (in thousands) Amount Pro forma revenue $ 256,163 Pro forma net loss 27,143 The unaudited pro forma financial information for all periods presented adjusts for the effects of material business combination items, including amortization of acquired intangible assets, transaction-related costs, adjustments to interest expense related to the assumption of long-term debt, retention and severance bonuses and the corresponding income tax effects of each. These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the Progenics Acquisition actually taken place on January 1, 2019. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the Progenics Acquisition, including, but not limited to, revenue enhancements, cost savings or operating synergies that the combined company may achieve as a result of the Progenics Acquisition.

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Sale of Puerto Rico Subsidiary	Sale of Puerto Rico Subsidiary During the fourth quarter of 2020, the Company entered into a stock purchase agreement (the “SPA”) with one of its existing radiopharmacy customers to sell all the stock of its Puerto Rico radiopharmacy subsidiary. The assets were classified as held for sale and the Company determined that the fair value of the net assets being sold significantly exceeded the carrying value as of December 31, 2020. The transaction was consummated on January 29, 2021. The purchase price for the stock sale was $18.0 million in cash, which includes a holdback amount of $1.8 million to be due to the Company in January 2022; the purchase price also included a working capital adjustment. The SPA contains customary representations, warranties and covenants by each of the parties. Subject to certain limitations, the buyer will be indemnified for damages resulting from breaches or inaccuracies of the Company’s representations, warranties and covenants in the SPA. As part of the transaction, the Company and the buyer also entered into a customary transition services agreement and a long-term supply contract under which the Company will supply the buyer with certain of the Company’s products on commercial terms and under which the buyer has agreed to certain product minimum purchase commitments. The Company does not believe this sale of certain net assets, reported as held for sale in the international segment prior to the change in segments in the first quarter of 2021, constituted a strategic shift that would have a major effect on its operations or financial results. As a result, this transaction is not classified as discontinued operations in the Company’s accompanying condensed consolidated financial statements. The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale) and held for sale as of December 31, 2020: (in thousands) January 29, 2021 December 31, 2020 Current Assets: Cash and cash equivalents $ 540 $ 941 Accounts receivable, net 1,959 2,191 Inventory 530 420 Other current assets 65 43 Total current assets 3,094 3,595 Non-Current Assets: Property, plant & equipment, net 780 761 Intangibles, net 96 96 Other long-term assets 774 790 Total assets held for sale $ 4,744 $ 5,242 Current Liabilities: Accounts payable $ 185 $ 224 Accrued expense and other liabilities 369 661 Total current liabilities 554 885 Non-Current Liabilities: Asset retirement obligations 306 302 Other long-term liabilities 588 606 Total liabilities held for sale $ 1,448 $ 1,793 The sale resulted in a pre-tax book gain of $15.3 million, which was recorded within operating income in the condensed consolidated statements of operations for the nine months ended September 30, 2021.

Asset Retirement Obligations

Asset Retirement Obligations	9 Months Ended
	Sep. 30, 2021
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligations	Asset Retirement Obligations The Company considers its legal obligation to remediate its facilities upon a decommissioning of its radioactive-related operations as an asset retirement obligation. The Company has production facilities which manufacture and process radioactive materials at its North Billerica, Massachusetts site. As of September 30, 2021, the liability is measured at the present value of the obligation expected to be incurred, of approximately $26.4 million. The Company previously operated a production facility which manufactured and processed radioactive materials at its San Juan, Puerto Rico site. As of December 31, 2020, the liability for the San Juan, Puerto Rico site was recorded in liabilities held for sale and the sale was consummated on January 29, 2021. The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2021 $ 14,020 Accretion expense 1,165 Balance at September 30, 2021 $ 15,185 The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company’s ability to fund the decommissioning of its North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a $28.2 million surety bond.

Intangibles, Net

Intangibles, Net	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, Net	Intangibles, NetIntangibles, net, consisted of the following: September 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,372) $ 2,168 Customer relationships Accelerated 96,923 (94,461) 2,462 Currently marketed products Straight-Line 275,700 (17,275) 258,425 Licenses Straight-Line 85,800 (9,668) 76,132 Developed technology Straight-Line 2,400 (344) 2,056 IPR&D N/A 15,640 — 15,640 Total $ 490,003 $ (133,120) $ 356,883 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012 The Company recorded amortization expense for its intangible assets of $8.4 million and $4.8 million for the three months ended September 30, 2021 and 2020, respectively, and $19.1 million and $6.1 million for the nine months ended September 30, 2021 and 2020, respectively. In May 2021, PyL (18F-DCFPyL) was approved by the FDA under the name PYLARIFY. Accordingly, the Company reclassified the associated asset of $132.8 million from IPR&D to currently marketed products and commenced amortization of the asset. The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2021 $ 8,370 2022 33,233 2023 32,634 2024 32,563 2025 32,508 2026 and thereafter 201,935 Total $ 341,243

Long-Term Debt, Net, and Other

Long-Term Debt, Net, and Other Borrowings	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt, Net, and Other Borrowings	Long-Term Debt, Net, and Other Borrowings As of September 30, 2021, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2021 $ 2,500 2022 11,250 2023 15,000 2024 148,750 Total principal outstanding 177,500 Unamortized debt discount (548) Unamortized debt issuance costs (473) Finance lease liabilities 618 Total 177,097 Less: current portion (10,356) Total long-term debt, net and other borrowings $ 166,741 At September 30, 2021, the Company’s interest rate under the five-year secured term loan facility, which matures on June 30, 2024 (the “2019 Term Facility”) was 2.1%. On March 31, 2021, the Company voluntarily repaid in full the entire outstanding principal on the original $50.0 million loan agreement (the “Royalty-Backed Loan”) with a fund managed by HealthCare Royalty Partners III, L.P. in the amount of $30.9 million, which included a prepayment amount of $0.5 million, and terminated the agreement governing the Royalty-Backed Loan. The Company recorded a gain on extinguishment of debt of $0.9 million related to the write-off of an unamortized debt premium offset by the prepayment amount.

Derivative Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	Derivative Instruments The Company uses interest rate swaps to reduce the variability in cash flows associated with a portion of the Company’s forecasted interest payments on its variable rate debt. In March 2020, the Company entered into interest rate swap contracts to fix the LIBOR rate on a notional amount of $100.0 million through May 31, 2024. The average fixed LIBOR rate on the interest rate swaps is approximately 0.82%. This agreement involves the receipt of floating rate amounts in exchange for fixed rate interest payments over the life of the agreement without an exchange of the underlying principal amount. The interest rate swaps were designated as cash flow hedges. In accordance with hedge accounting, the interest rate swaps are recorded on the Company’s condensed consolidated balance sheets at fair value, and changes in the fair value of the swap agreements are recorded to other comprehensive loss and reclassified to interest expense in the period during which the hedged transaction affected earnings or it will become probable that the forecasted transaction would not occur. At September 30, 2021, accumulated other comprehensive loss included $0.7 million of pre-tax deferred losses that are expected to be reclassified to earnings during the next 12 months. The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets: (in thousands) September 30, 2021 December 31, 2020 Derivatives type Classification Liabilities: Interest rate swap Accrued expenses and other liabilities $ 766 $ 1,908

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive LossThe components of accumulated other comprehensive loss, net of tax of $0.2 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive income before reclassifications 55 312 367 Amounts reclassified to earnings — 539 539 Balance at September 30, 2021 $ (575) $ (567) $ (1,142) Balance at January 1, 2020 $ (960) $ — $ (960) Other comprehensive loss before reclassifications (9) (1,784) (1,793) Amounts reclassified to earnings — 243 243 Balance at September 30, 2020 $ (969) $ (1,541) $ (2,510)

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Cost of goods sold $ 144 $ 864 $ 1,672 $ 2,127 Sales and marketing 684 621 1,726 1,268 General and administrative 2,330 1,926 6,641 5,735 Research and development 709 581 1,733 1,322 Total stock-based compensation expense $ 3,867 $ 3,992 $ 11,772 $ 10,452

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share A summary of net loss per common share is presented below: Three Months Ended Nine Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Net loss $ (13,415) $ (6,386) $ (31,064) $ (10,061) Basic weighted-average common shares outstanding 67,623 66,820 67,409 49,858 Basic and diluted loss per common share $ (0.20) $ (0.10) $ (0.46) $ (0.20) Antidilutive securities excluded from diluted net income per common share 3,051 2,588 3,051 1,657

Other Loss (Income)

Other Loss (Income)	9 Months Ended
	Sep. 30, 2021
Other Income and Expenses [Abstract]
Other Loss (Income)	Other Loss (Income) Other loss (income) consisted of the following: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Foreign currency losses (gains) $ 127 $ (33) $ 156 $ 187 Tax indemnification loss (income), net 3,823 (555) 3,092 (1,664) Interest income (11) (7) (39) (221) Other 1 (1) — (4) Total other loss (income) $ 3,940 $ (596) $ 3,209 $ (1,702)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The costs and outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements. As of September 30, 2021, the Company had the following material ongoing litigation in which the Company was a party: RELISTOR European Opposition Proceedings In October 2015, Progenics received notices of opposition to three European patents relating to methylnaltrexone: EP1615646, EP2368553 and EP2368554. Notices of opposition were filed separately at the European Patent Office (the “EPO”) by each of Actavis Group PTC ehf and Fresenius Kabi Deutschland GmbH. Between May 11, 2017 and July 4, 2017, the Opposition Division of the EPO (the “Opposition Division”) provided notice that the three European patents would be revoked. Each of these matters was appealed to the Appeal Board of the EPO. On November 13, 2020, Progenics withdrew the appeal for EP2368553 and EP2368554. Notices of termination of the proceedings with revocation of the patent were issued on November 23, 2020 for both patents. Progenics continued its appeal for the revocation of the third patent, EP1615646. Oral proceedings for EP1615646 were held at the Appeal Board of the EPO on September 22, 2020. The revocation decision under appeal was set aside and the case was remitted to the Opposition Division for further prosecution. An oral hearing was held before the Opposition Division on September 27, 2021. The parties are awaiting the final written decision of the Opposition Division. The final written decision of the Opposition Division is appealable to the Appeal Board of the EPO by either party. Because the outcome of opposition and appeal proceedings at the EPO is uncertain, the Company cannot predict how or when this matter will ultimately be resolved. German PSMA-617 Litigation On November 8, 2018, Molecular Insight Pharmaceuticals, Inc., a subsidiary of Progenics (“MIP”), filed a complaint against the University of Heidelberg (the “University”) in the District Court in Mannheim, Germany (the “German District Court”). In this Complaint, MIP claimed that the discovery and development of PSMA-617 was related to work performed under a research collaboration sponsored by MIP. MIP alleged that the University breached certain contracts with MIP and that MIP is the co-owner of inventions embodied in certain worldwide patent filings related to PSMA-617 that were filed by the University. On February 27, 2019, Endocyte, Inc., a wholly owned subsidiary of Novartis AG, filed a motion to intervene in the German litigation. Endocyte is the exclusive licensee of the patent rights that are the subject of the German proceedings. On November 27, 2018, MIP requested that the EPO stay the examination of a certain European Patent and related Divisional Applications, pending a decision from the German District Court on MIP’s Complaint. On December 10, 2018, the EPO granted MIP’s request and stayed the examination of the patent and patent applications effective November 27, 2018. MIP filed a Confirmation of Ownership with the United States Patent and Trademark Office (“USPTO”) in corresponding U.S. patent applications (U.S. Serial Nos. 15/131,118; 15/805,900; 16/038,729, 16/114,988, 16/510,495, 16/551,198, and 17/110,558). MIP’s filing with the USPTO takes the position that, in light of the collaboration and contracts between MIP and the University, MIP is the co-owner of these pending U.S. patent applications (U.S. Serial Nos. 16/510,495, 16/551,198). On March 6, 2020, MIP filed with the USPTO a notice stating that the Power of Attorney in certain pending U.S. patent applications was signed by less than all applicants or owners of the applications. On February 27, 2019, the German District Court set €0.4 million as the amount MIP must deposit with the German District Court as security in the event of an unfavorable final decision on the merits of the dispute. The German District Court held the first oral hearing in the case on August 6, 2019. The German District Court considered procedural matters and granted the parties the right to make further submissions. A further oral hearing occurred July 23, 2020, during which the German District Court heard live testimony from several witnesses, testifying on behalf of the defendants. On August 24, 2020, the German District Court issued its decision dismissing MIP’s claims, stating that MIP failed to discharge its burden of proof in the matter. MIP filed a Notice of Appeal of the German District Court’s decision on September 24, 2020 and filed its appeal brief on November 26, 2020. The University and Endocyte each filed oppositions to MIP’s Notice of Appeal on March 12, 2021. An oral hearing for the appeal is scheduled for February 9, 2022, at the Higher Regional Court Karlsruhe. MIP is also considering its legal and procedural alternatives against the defendants in other jurisdictions and proceedings. If MIP is not successful in its appeal, it will be responsible for the German court fees and fees and disbursements of defendant’s and intervenor’s counsel, both at first instance and on appeal. Most of such fees and disbursements at first instance are covered by a cash security deposited with the German District Court. Because the outcome of litigation is uncertain, the Company cannot predict how or when this matter will ultimately be resolved. Petition for Post-Grant Review

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment InformationIn the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, including the impact on the Company’s business of the acquisition of Progenics described in Notes 1 and 8, and the sale of the Puerto Rico subsidiary in the first quarter, which resulted in a change in operating and reportable segments. The Company now operates as one business segment: the development, manufacture and sale of innovative diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. This conclusion reflects the Company’s focus on the performance of the business on a consolidated worldwide basis. The results of this operating segment are regularly reviewed by the Company’s chief operating decision maker, the President and Chief Executive Officer. The Company’s chief operating decision maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn October 11, 2021, the Company signed a sublease for certain office space. See Note 16, “Leases”, for further details.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Leases Operating and finance lease assets and liabilities are as follows: (in thousands) Classification September 30, December 31, Assets Operating Other long-term assets $ 8,287 $ 18,441 Finance Property, plant and equipment, net 508 525 Total leased assets $ 8,795 $ 18,966 Liabilities Current Operating Accrued expenses and other liabilities $ 1,397 $ 1,164 Finance Current portion of long-term debt and other borrowings 356 249 Noncurrent Operating Other long-term liabilities 16,391 17,501 Finance Long-term debt, net and other borrowings 262 246 Total leased liabilities $ 18,406 $ 19,160
Leases	Leases Operating and finance lease assets and liabilities are as follows: (in thousands) Classification September 30, December 31, Assets Operating Other long-term assets $ 8,287 $ 18,441 Finance Property, plant and equipment, net 508 525 Total leased assets $ 8,795 $ 18,966 Liabilities Current Operating Accrued expenses and other liabilities $ 1,397 $ 1,164 Finance Current portion of long-term debt and other borrowings 356 249 Noncurrent Operating Other long-term liabilities 16,391 17,501 Finance Long-term debt, net and other borrowings 262 246 Total leased liabilities $ 18,406 $ 19,160

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements include the accounts of Holdings and its direct and indirect wholly-owned subsidiaries, including Progenics (as of the Closing Date, as defined below), and have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all of the information and notes required by generally accepted accounting principles in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement have been included. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ended December 31, 2021 or any future period. In the first quarter of fiscal year 2021, the Company completed the evaluation of its operating and reporting structure, which resulted in a change in operating segments. Please refer to Note 20, “Segment Information”, for further details. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities Exchange Commission (“SEC”) on February 25, 2021.
Reclassifications	Reclassifications Certain immaterial reclassifications in the prior period condensed consolidated statements of cash flows have been reclassified to conform to the current year period financial statement presentation. Reclassifications include $0.2 million from provision for bad debt to other at September 30, 2020. The Company had a reclassification in presentation related to rebates and allowances within product revenue. Please refer to Note 3, “Revenue from Contracts with Customers” for further details.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Nine Months Ended September 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Standard Description Effect on the Condensed Consolidated Financial Statements Accounting Standards Adopted During the Nine Months Ended September 30, 2021 ASU 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” This ASU provides guidance to simplify the complexity associated with accounting for convertible instruments and derivatives. For convertible instruments, the number of major separation models required were reduced. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. This ASU further amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The ASU simplifies the diluted net income per share calculation in certain areas as well. January 1, 2021 The adoption of this standard did not have a material impact on the Company’s condensed consolidated financial statements.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following table summarizes revenue by revenue source as follows: Three Months Ended Nine Months Ended Major Products/Service Lines (in thousands) 2021 2020 2021 2020 Product revenue, net (1) $ 96,678 $ 83,661 $ 277,559 $ 238,801 License and royalty revenues 5,395 4,883 18,087 6,457 Total revenues $ 102,073 $ 88,544 $ 295,646 $ 245,258 ________________________________ (1) The Company’s principal products include DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products. The Company classifies its revenues into three product categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships and other. Precision diagnostics includes DEFINITY, TechneLite and other imaging diagnostic products. Radiopharmaceutical oncology consists primarily of PYLARIFY and AZEDRA. Strategic partnerships and other includes partnerships related to other products of the Company, such as RELISTOR. Revenue by product category on a net basis is as follows: Three Months Ended Nine Months Ended (in thousands) 2021 2020 (1) 2021 2020 (1) DEFINITY $ 57,636 $ 50,359 $ 173,448 $ 139,989 TechneLite 22,680 21,113 69,252 62,560 Other precision diagnostics 7,563 8,585 21,289 28,782 Total precision diagnostics 87,879 80,057 263,989 231,331 Radiopharmaceutical oncology 8,890 3,323 13,203 7,474 Strategic partnerships and other 5,304 5,164 18,454 6,453 Total revenues $ 102,073 $ 88,544 $ 295,646 $ 245,258 ________________________________ (1) The Company reclassified rebates and allowances of $5.5 million and $13.8 million within each product category, which included $5.1 million and $12.6 million for DEFINITY, $0.3 million and $0.9 million for TechneLite and $0.1 million and $0.2 million for other precision diagnostics, for the three and nine months ended September 30, 2020, respectively.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities measured at fair value on a recurring basis	The tables below present information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2021 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 39,141 $ 39,141 $ — $ — Contingent receivable 13,800 — — 13,800 Total assets $ 52,941 $ 39,141 $ — $ 13,800 Liabilities: Interest rate swaps $ 766 $ — $ 766 $ — Contingent consideration liabilities 46,800 — — 46,800 Total liabilities $ 47,566 $ — $ 766 $ 46,800 December 31, 2020 (in thousands) Total Fair Level 1 Level 2 Level 3 Assets: Money market $ 35,457 $ 35,457 $ — $ — Contingent receivable 11,300 — — 11,300 Total assets $ 46,757 $ 35,457 $ — $ 11,300 Liabilities: Interest rate swaps $ 1,908 $ — $ 1,908 $ — Contingent consideration liabilities 15,800 — — 15,800 Total liabilities $ 17,708 $ — $ 1,908 $ 15,800
Fair Value Measurement Inputs and Valuation Techniques	The following tables summarize quantitative information and assumptions pertaining to the fair value measurement of assets and liabilities using Level 3 inputs at September 30, 2021. Fair Value at Assumptions (in thousands) September 30, 2021 December 31, 2020 Valuation Technique Unobservable Input September 30, 2021 December 31, 2020 Contingent receivable: Regulatory milestone $ 3,300 $ 3,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2022 2021 Probability of success 90 % 90 % Discount rate 18 % 24 % Royalties 10,500 8,100 Probability adjusted discounted cash flow model Probability of success 13% - 77% 13% - 77% Discount rate 18 % 24 % Total $ 13,800 $ 11,300 Fair Value at Assumptions (in thousands) September 30, 2021 December 31, 2020 Valuation Technique Unobservable Input September 30, 2021 December 31, 2020 Contingent consideration liability: Net sales targets - PYLARIFY (CVRs) $ 33,200 $ 4,200 Monte Carlo simulation Period of expected milestone achievement 2022 - 2023 2022 - 2023 Discount rate 18 % 24 % 1095 commercialization milestone 1,900 2,200 Probability adjusted discounted cash flow model Period of expected milestone achievement 2026 2026 Probability of success 40 % 45 % Discount rate 0.9 % 0.5 % Net sales targets - AZEDRA and 1095 11,700 9,400 Monte Carlo simulation Probability of success 40% - 100% 40% - 100% Discount rate 17% - 18% 23% - 24% Total $ 46,800 $ 15,800
Schedule of financial instruments with significant Level 3 inputs	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated: Financial Assets Financial Liabilities (in thousands) Nine Months Ended Nine Months Ended 2021 2020 2021 2020 Fair value, beginning of period $ 11,300 $ — $ 15,800 $ — Progenics acquisition — 10,100 — 16,300 Changes in fair value included in net loss 2,500 100 31,000 900 Fair value, end of period $ 13,800 $ 10,200 $ 46,800 $ 17,200

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of income tax expense	: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Income tax (benefit) expense $ (6,422) $ (1,076) $ (2,967) $ 1,425

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventory consisted of the following: (in thousands) September 30, December 31, Raw materials $ 15,173 $ 16,000 Work in process 11,560 11,212 Finished goods 7,216 8,532 Total inventory $ 33,949 $ 35,744

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property, plant, and equipment, net	Property, plant and equipment, net, consisted of the following: (in thousands) September 30, December 31, Land $ 13,450 $ 13,450 Buildings 73,285 70,381 Machinery, equipment and fixtures 82,596 77,854 Computer software 24,223 23,644 Construction in progress 8,887 11,254 202,441 196,583 Less: accumulated depreciation and amortization (86,000) (76,412) Total property, plant and equipment, net $ 116,441 $ 120,171

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of business acquisition	The acquisition date fair value of the consideration transferred in the acquisition consisted of the following: (in thousands) Amount Issuance of common stock $ 398,110 Fair value of replacement options 7,125 Fair value of bridge loan settled at close 10,074 Fair value of contingent considerations (CVRs) 3,700 Total consideration transferred (1) $ 419,009 (1) Non-cash investing and financing activities in the condensed consolidated statements of cash flows
Schedule of fair value disclosure of asset and liability	The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made to the amounts initially recorded in June 2020. The measurement period adjustments primarily resulted from finalizing the fair values of certain intangible assets and liabilities, deferred taxes and other changes to certain tangible assets and liability accounts. Measurement period adjustments were recognized in the reporting period in which the adjustments were determined and calculated as if the accounting had been completed at the acquisition date. The related impact to net loss that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. (in thousands) Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 15,421 $ — $ 15,421 Accounts receivable 5,787 — 5,787 Inventory 915 160 1,075 Other current assets 3,250 434 3,684 Property, plant and equipment 14,972 — 14,972 Identifiable intangible assets (weighted average useful life): Currently marketed product (15 years) 142,100 800 142,900 Licenses (11.5 years) 87,500 (1,700) 85,800 Developed technology (9 years) 3,000 (600) 2,400 IPR&D 150,900 200 151,100 Other long-term assets 37,631 — 37,631 Accounts payable (1,616) — (1,616) Accrued expenses and other liabilities (8,207) (80) (8,287) Other long-term liabilities (30,778) (380) (31,158) Long-term debt and other borrowings (40,200) — (40,200) Deferred tax liabilities (3,717) (2,258) (5,975) Goodwill 42,051 3,424 45,475 Total consideration transferred $ 419,009 $ — $ 419,009
Schedule pro forma financial information	The following unaudited pro forma financial information presents the Company’s results as if the Progenics Acquisition had occurred on January 1, 2019: Nine Months Ended (in thousands) Amount Pro forma revenue $ 256,163 Pro forma net loss 27,143

Sale of Puerto Rico Subsidiary

Sale of Puerto Rico Subsidiary (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Disposal groups including discontinued operations	The following table summarizes the major classes of assets and liabilities sold as of January 29, 2021 (date of sale) and held for sale as of December 31, 2020: (in thousands) January 29, 2021 December 31, 2020 Current Assets: Cash and cash equivalents $ 540 $ 941 Accounts receivable, net 1,959 2,191 Inventory 530 420 Other current assets 65 43 Total current assets 3,094 3,595 Non-Current Assets: Property, plant & equipment, net 780 761 Intangibles, net 96 96 Other long-term assets 774 790 Total assets held for sale $ 4,744 $ 5,242 Current Liabilities: Accounts payable $ 185 $ 224 Accrued expense and other liabilities 369 661 Total current liabilities 554 885 Non-Current Liabilities: Asset retirement obligations 306 302 Other long-term liabilities 588 606 Total liabilities held for sale $ 1,448 $ 1,793

Asset Retirement Obligations (T

Asset Retirement Obligations (Tables)	9 Months Ended
	Sep. 30, 2021
Asset Retirement Obligation Disclosure [Abstract]
Summary of changes in asset retirement obligations	The following table provides a summary of the changes in the Company’s asset retirement obligations: (in thousands) Amount Balance at January 1, 2021 $ 14,020 Accretion expense 1,165 Balance at September 30, 2021 $ 15,185

Intangibles, Net (Tables)

Intangibles, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangibles	Intangibles, net, consisted of the following: September 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,372) $ 2,168 Customer relationships Accelerated 96,923 (94,461) 2,462 Currently marketed products Straight-Line 275,700 (17,275) 258,425 Licenses Straight-Line 85,800 (9,668) 76,132 Developed technology Straight-Line 2,400 (344) 2,056 IPR&D N/A 15,640 — 15,640 Total $ 490,003 $ (133,120) $ 356,883 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012
Schedule of intangibles	Intangibles, net, consisted of the following: September 30, 2021 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (11,372) $ 2,168 Customer relationships Accelerated 96,923 (94,461) 2,462 Currently marketed products Straight-Line 275,700 (17,275) 258,425 Licenses Straight-Line 85,800 (9,668) 76,132 Developed technology Straight-Line 2,400 (344) 2,056 IPR&D N/A 15,640 — 15,640 Total $ 490,003 $ (133,120) $ 356,883 December 31, 2020 (in thousands) Amortization Method Cost Accumulated Amortization Net Trademarks Straight-Line $ 13,540 $ (10,958) $ 2,582 Customer relationships Accelerated 96,865 (93,770) 3,095 Currently marketed product Straight-Line 142,900 (5,053) 137,847 Licenses Straight-Line 85,800 (4,008) 81,792 Developed technology Straight-Line 2,400 (144) 2,256 IPR&D N/A 148,440 — 148,440 Total $ 489,945 $ (113,933) $ 376,012
Schedule of expected future amortization expense	The below table summarizes the estimated aggregate amortization expense expected to be recognized on the above intangible assets: (in thousands) Amount Remainder of 2021 $ 8,370 2022 33,233 2023 32,634 2024 32,563 2025 32,508 2026 and thereafter 201,935 Total $ 341,243

Long-Term Debt, Net, and Othe_2

Long-Term Debt, Net, and Other Borrowings (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of maturities of principal obligations	As of September 30, 2021, the Company’s maturities of principal obligations under its long-term debt and other borrowings are as follows: (in thousands) Amount Remainder of 2021 $ 2,500 2022 11,250 2023 15,000 2024 148,750 Total principal outstanding 177,500 Unamortized debt discount (548) Unamortized debt issuance costs (473) Finance lease liabilities 618 Total 177,097 Less: current portion (10,356) Total long-term debt, net and other borrowings $ 166,741

Derivative Instruments (Tables)

Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative instruments	The following table presents the location and fair value amounts of derivative instruments reported in the condensed consolidated balance sheets: (in thousands) September 30, 2021 December 31, 2020 Derivatives type Classification Liabilities: Interest rate swap Accrued expenses and other liabilities $ 766 $ 1,908

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of accumulated other comprehensive loss	The components of accumulated other comprehensive loss, net of tax of $0.2 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively, consisted of the following: (in thousands) Foreign currency translation Unrealized loss on cash flow hedges Accumulated other comprehensive loss Balance at January 1, 2021 $ (630) $ (1,418) $ (2,048) Other comprehensive income before reclassifications 55 312 367 Amounts reclassified to earnings — 539 539 Balance at September 30, 2021 $ (575) $ (567) $ (1,142) Balance at January 1, 2020 $ (960) $ — $ (960) Other comprehensive loss before reclassifications (9) (1,784) (1,793) Amounts reclassified to earnings — 243 243 Balance at September 30, 2020 $ (969) $ (1,541) $ (2,510)

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense recognized	The following table presents stock-based compensation expense recognized in the Company’s accompanying condensed consolidated statements of operations: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Cost of goods sold $ 144 $ 864 $ 1,672 $ 2,127 Sales and marketing 684 621 1,726 1,268 General and administrative 2,330 1,926 6,641 5,735 Research and development 709 581 1,733 1,322 Total stock-based compensation expense $ 3,867 $ 3,992 $ 11,772 $ 10,452

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Summary of net loss per common share	A summary of net loss per common share is presented below: Three Months Ended Nine Months Ended (in thousands, except per share amounts) 2021 2020 2021 2020 Net loss $ (13,415) $ (6,386) $ (31,064) $ (10,061) Basic weighted-average common shares outstanding 67,623 66,820 67,409 49,858 Basic and diluted loss per common share $ (0.20) $ (0.10) $ (0.46) $ (0.20) Antidilutive securities excluded from diluted net income per common share 3,051 2,588 3,051 1,657

Other Loss (Income) (Tables)

Other Loss (Income) (Tables)	9 Months Ended
	Sep. 30, 2021
Other Income and Expenses [Abstract]
Schedule of Other Loss (Income)	Other loss (income) consisted of the following: Three Months Ended Nine Months Ended (in thousands) 2021 2020 2021 2020 Foreign currency losses (gains) $ 127 $ (33) $ 156 $ 187 Tax indemnification loss (income), net 3,823 (555) 3,092 (1,664) Interest income (11) (7) (39) (221) Other 1 (1) — (4) Total other loss (income) $ 3,940 $ (596) $ 3,209 $ (1,702)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of operating and finance lease assets and liabilities	Operating and finance lease assets and liabilities are as follows: (in thousands) Classification September 30, December 31, Assets Operating Other long-term assets $ 8,287 $ 18,441 Finance Property, plant and equipment, net 508 525 Total leased assets $ 8,795 $ 18,966 Liabilities Current Operating Accrued expenses and other liabilities $ 1,397 $ 1,164 Finance Current portion of long-term debt and other borrowings 356 249 Noncurrent Operating Other long-term liabilities 16,391 17,501 Finance Long-term debt, net and other borrowings 262 246 Total leased liabilities $ 18,406 $ 19,160

Basis of Presentation (Details)

Basis of Presentation (Details) $ / shares in Units, $ in Thousands	Feb. 20, 2020USD ($)contingent_value_right$ / sharesshares	Sep. 30, 2021USD ($)day$ / shares	Dec. 31, 2020USD ($)$ / shares	Jun. 19, 2020USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.01	$ 0.01
Contingent consideration liabilities		$ 46,800	$ 15,800
Business combination, consideration transferred, equity interests issued (in shares) | shares	26,844,877
Business combination common stock under contingent value right (in shares) | shares	86,630,633
Maximum
Business Acquisition [Line Items]
No of working days | day		5
Minimum
Business Acquisition [Line Items]
No of working days | day		4
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.0013
Progenics
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares to be received from acquisition conversion (in shares) | shares	0.31
Number of CVRs | contingent_value_right	1
Percentage of net sales, contingent consideration	40.00%
Contingent consideration liabilities				$ 3,700
Percentage of total contingent consideration under CVRs	19.90%
Business combination contingent value right of total consideration	$ 100,000
Progenics | Cash Payments 2022
Business Acquisition [Line Items]
Contingent consideration liabilities	100,000
Progenics | Cash Payments 2023
Business Acquisition [Line Items]
Contingent consideration liabilities	$ 150,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended
	Sep. 30, 2020USD ($)
Revision of Prior Period, Reclassification, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision for bad debt	$ (0.2)

Revenue from Contracts with C_3

Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 102,073	$ 88,544	$ 295,646	$ 245,258
Reclassification of rebates and allowances		5,500		13,800
Product revenue, net
Disaggregation of Revenue [Line Items]
Revenues	96,678	83,661	277,559	238,801
License and royalty revenues
Disaggregation of Revenue [Line Items]
Revenues	5,395	4,883	18,087	6,457
Total precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	87,879	80,057	263,989	231,331
DEFINITY
Disaggregation of Revenue [Line Items]
Revenues	57,636	50,359	173,448	139,989
Reclassification of rebates and allowances		5,100		12,600
TechneLite
Disaggregation of Revenue [Line Items]
Revenues	22,680	21,113	69,252	62,560
Reclassification of rebates and allowances		300		900
Other precision diagnostics
Disaggregation of Revenue [Line Items]
Revenues	7,563	8,585	21,289	28,782
Reclassification of rebates and allowances		100		200
Radiopharmaceutical oncology
Disaggregation of Revenue [Line Items]
Revenues	8,890	3,323	13,203	7,474
Strategic partnerships and other
Disaggregation of Revenue [Line Items]
Revenues	$ 5,304	$ 5,164	$ 18,454	$ 6,453

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on A Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	$ 13,800	$ 11,300
Total assets	52,941	46,757
Contingent consideration liabilities	46,800	15,800
Total liabilities	47,566	17,708
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	39,141	35,457
Contingent consideration liabilities	0	0
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	0	0
Total assets	0	0
Contingent consideration liabilities	0	0
Total liabilities	766	1,908
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent receivable	13,800	11,300
Total assets	13,800	11,300
Contingent consideration liabilities	46,800	15,800
Total liabilities	46,800	15,800
Interest Rate Swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	766	1,908
Interest Rate Swaps | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Interest Rate Swaps | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	766	1,908
Interest Rate Swaps | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swaps	0	0
Money market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	39,141	35,457
Money market | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	39,141	35,457
Money market | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	0	0
Money market | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone	$ 102,073	$ 88,544	$ 295,646	$ 245,258
Progenics Pharmaceuticals Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Royalty percentage			0.05
Potential payments, high	85,000		$ 85,000
Progenics Pharmaceuticals Inc | Net Sales Targets For Azedra
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high	70,000		70,000
Progenics Pharmaceuticals Inc | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Potential payments, high	5,000		5,000
Progenics Pharmaceuticals Inc | 1404 Commercialization Milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Business combination, contingent consideration arrangements, range of outcomes not reasonably possible, value	$ 10,000		10,000
Royalty | Progenics Pharmaceuticals Inc
Fair Value, Option, Quantitative Disclosures [Line Items]
Company acquired right to receive certain future milestone			$ 5,000

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Quantitative Information and Assumptions Pertaining To The Fair Value Measurement of The Level 3 Inputs (Details) $ in Thousands	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	$ 13,800	$ 11,300
Contingent consideration liabilities	46,800	15,800
Level 3
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	13,800	11,300
Contingent consideration liabilities	46,800	15,800
Level 3 | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	3,300	3,200
Level 3 | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent receivable	10,500	8,100
Level 3 | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	33,200	4,200
Level 3 | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	1,900	2,200
Level 3 | Net sales targets - AZEDRA and 1095
Fair Value, Option, Quantitative Disclosures [Line Items]
Contingent consideration liabilities	$ 11,700	$ 9,400
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.90	0.90
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.13	0.13
Level 3 | Probability adjusted discounted cash flow model | Probability of success | Royalties | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.77	0.77
Level 3 | Probability adjusted discounted cash flow model | Probability of success | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.45
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Regulatory milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.24
Level 3 | Probability adjusted discounted cash flow model | Discount rate | Royalties
Fair Value, Option, Quantitative Disclosures [Line Items]
Asset measurement input	0.18	0.24
Level 3 | Probability adjusted discounted cash flow model | Discount rate | 1095 commercialization milestone
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.009	0.005
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.40	0.40
Level 3 | Monte Carlo simulation | Probability of success | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	1	1
Level 3 | Monte Carlo simulation | Discount rate | CVRs
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.24
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.17	0.23
Level 3 | Monte Carlo simulation | Discount rate | Net sales targets - AZEDRA and 1095 | Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Liability measurement input	0.18	0.24

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Financial Instruments With Significant Level 3 Inputs (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Financial Assets
Fair value, beginning of period	$ 11,300	$ 0
Progenics acquisition	0	10,100
Changes in fair value included in net loss	2,500	100
Fair value, end of period	13,800	10,200
Financial Liabilities
Fair value, beginning of period	15,800	0
Progenics acquisition	0	16,300
Changes in fair value included in net loss	31,000	900
Fair value, end of period	46,800	$ 17,200
Change in fair value of the contingent financial asset and contingent financial liabilities	$ 28,500

Income Taxes (Detail)

Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Valuation Allowance [Line Items]
Income tax (benefit) expense	$ (6,422)		$ (1,076)	$ (2,967)	$ 1,425
Settlement agreement	5,500
Decrease from uncertain tax positions				700
Decrease in income tax penalties and interest expense, uncertain tax positions				500
Decrease from prior uncertain tax positions				100
Decrease in income tax penalties and interest expense, prior uncertain tax positions				400
Reduction from lapse of statute of limitations				200
Goodwill acquired		$ 2,600
UNITED KINGDOM
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	1,200			1,200
SWEDEN
Valuation Allowance [Line Items]
Deferred tax asset, valuation allowance	$ 2,000			$ 2,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory [Line Items]
Raw materials	$ 15,173	$ 16,000
Work in process	11,560	11,212
Finished goods	7,216	8,532
Total inventory	33,949	$ 35,744
DEFINITY
Inventory [Line Items]
Total inventory	$ 3,200

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 202,441		$ 202,441		$ 196,583
Less: accumulated depreciation and amortization	(86,000)		(86,000)		(76,412)
Total property, plant and equipment, net	116,441		116,441		120,171
Depreciation and amortization expense	3,600	$ 3,400	9,800	$ 9,100
Impairment of long-lived assets			9,540	$ 7,275
Land
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	13,450		13,450		13,450
Buildings
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	73,285		73,285		70,381
Machinery, equipment and fixtures
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	82,596		82,596		77,854
Computer software
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	24,223		24,223		23,644
Construction in progress
Property, Plant & Equipment [Line Items]
Property, plant & equipment, gross	$ 8,887		$ 8,887		$ 11,254

Business Combinations - Narrati

Business Combinations - Narrative (Details) $ in Thousands	Jun. 19, 2020USD ($)	Mar. 31, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Goodwill					$ 61,189	$ 58,632
Progenics
Business Acquisition [Line Items]
Purchase price	$ 419,009
Fair value of bridge loan settled at close	10,074
Measurement period adjustment		$ 2,600
Acquired contingent receivable	10,100
Goodwill	$ 45,475
Acquisition related costs			$ 1,600	$ 10,500
Progenics | Discount rate
Business Acquisition [Line Items]
Measurement input					0.230

Business Combinations - Fair Va

Business Combinations - Fair Value of the Consideration Transferred in the Acquisition (Details) - USD ($) $ in Thousands	Jun. 19, 2020	Sep. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Fair value of contingent considerations (CVRs)		$ 46,800	$ 15,800
Progenics
Business Acquisition [Line Items]
Issuance of common stock	$ 398,110
Fair value of replacement options	7,125
Fair value of bridge loan settled at close	10,074
Fair value of contingent considerations (CVRs)	3,700
Total consideration transferred	$ 419,009

Business Combinations - Assets

Business Combinations - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 19, 2020	Sep. 30, 2021	Dec. 31, 2020
Business Combination Segment Allocation [Line Items]
Goodwill		$ 61,189	$ 58,632
Progenics
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	$ 15,421
Accounts receivable	5,787
Inventory	1,075
Other current assets	3,684
Property, plant and equipment	14,972
Identifiable intangible assets IPR&D	151,100
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,287)
Other long-term liabilities	(31,158)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(5,975)
Goodwill	45,475
Total consideration transferred	419,009
Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Cash and cash equivalents	15,421
Accounts receivable	5,787
Inventory	915
Other current assets	3,250
Property, plant and equipment	14,972
Identifiable intangible assets IPR&D	150,900
Other long-term assets	37,631
Accounts payable	(1,616)
Accrued expenses and other liabilities	(8,207)
Other long-term liabilities	(30,778)
Long-term debt and other borrowings	(40,200)
Deferred tax liabilities	(3,717)
Goodwill	42,051
Total consideration transferred	419,009
Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Inventory	160
Other current assets	434
Identifiable intangible assets IPR&D	200
Accrued expenses and other liabilities	(80)
Other long-term liabilities	(380)
Deferred tax liabilities	(2,258)
Goodwill	3,424
Total consideration transferred	0
Currently marketed products | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 142,900
Identifiable intangible assets useful lives	15 years
Currently marketed products | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 142,100
Currently marketed products | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	800
Licenses | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 85,800
Identifiable intangible assets useful lives	11 years 6 months
Licenses | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 87,500
Licenses | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	(1,700)
Developed technology | Progenics
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 2,400
Identifiable intangible assets useful lives	9 years
Developed technology | Progenics | Previously Reported
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ 3,000
Developed technology | Progenics | Revision of Prior Period, Adjustment
Business Combination Segment Allocation [Line Items]
Identifiable intangible assets	$ (600)

Business Combinations - Pro-For

Business Combinations - Pro-Forma (Details) - Progenics - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Business Acquisition [Line Items]
Revenue from acquiree	$ 5,900	$ 6,900
Loss from acquiree	$ 12,600	15,800
Pro forma revenue		256,163
Pro forma net loss		$ 27,143

Sale of Puerto Rico Subsidiar_2

Sale of Puerto Rico Subsidiary (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Jan. 29, 2021	Dec. 31, 2020
Current assets
Total current assets	$ 0		$ 5,242
Current liabilities
Total current liabilities	0		1,793
Puerto Rican Radiopharmacy Servicing Subsidiary
Non-Current Liabilities:
Pre-tax book gain on disposal	$ 15,300
Disposed of by Sale | Puerto Rican Radiopharmacy Servicing Subsidiary
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group consideration		$ 18,000
Disposal group holdback amount		1,800
Current assets
Cash and cash equivalents		540	941
Accounts receivable, net		1,959	2,191
Inventory		530	420
Other current assets		65	43
Total current assets		3,094	3,595
Non-Current Assets:
Property, plant & equipment, net		780	761
Intangibles, net		96	96
Other long-term assets		774	790
Total assets held for sale		4,744	5,242
Current liabilities
Accounts payable		185	224
Accrued expense and other liabilities		369	661
Total current liabilities		554	885
Non-Current Liabilities:
Asset retirement obligations		306	302
Other long-term liabilities		588	606
Total liabilities held for sale		$ 1,448	$ 1,793

Asset Retirement Obligations (D

Asset Retirement Obligations (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Asset Retirement Obligation Disclosure [Abstract]
Asset retirement obligation liabilities expected, present value	$ 26,400
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Asset retirement obligations, beginning balance	14,020
Accretion expense	1,165
Asset retirement obligations, ending balance	15,185
Financial assurance in form of surety bond	$ 28,200

Intangibles, Net - Schedule of

Intangibles, Net - Schedule of Intangibles, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Indefinite lived, Cost	$ 15,640	$ 148,440
Total, Cost	490,003	489,945
Accumulated Amortization	(133,120)	(113,933)
Total	341,243
Total, Net	356,883	376,012
Trademarks
Finite-Lived Intangible Assets [Line Items]
Cost	13,540	13,540
Accumulated Amortization	(11,372)	(10,958)
Total	2,168	2,582
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost	96,923	96,865
Accumulated Amortization	(94,461)	(93,770)
Total	2,462	3,095
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Cost	275,700	142,900
Accumulated Amortization	(17,275)	(5,053)
Total	258,425	137,847
Licenses
Finite-Lived Intangible Assets [Line Items]
Cost	85,800	85,800
Accumulated Amortization	(9,668)	(4,008)
Total	76,132	81,792
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost	2,400	2,400
Accumulated Amortization	(344)	(144)
Total	$ 2,056	$ 2,256

Intangibles, Net - Additional I

Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 8.4	$ 4.8	$ 19.1	$ 6.1
IPR & D
Finite-Lived Intangible Assets [Line Items]
Decrease in indefinite lived assets			132.8
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Increase in finite lived assets			$ 132.8

Intangibles, Net - Schedule o_2

Intangibles, Net - Schedule of Expected Future Amortization Expense Related to Intangible Assets (Details) $ in Thousands	Sep. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 8,370
2022	33,233
2023	32,634
2024	32,563
2025	32,508
2026 and thereafter	201,935
Total	$ 341,243

Long-Term Debt, Net, and Othe_3

Long-Term Debt, Net, and Other Borrowings (Details) - USD ($)	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Remainder of 2021		$ 2,500,000	$ 2,500,000
2022		11,250,000	11,250,000
2023		15,000,000	15,000,000
2024		148,750,000	148,750,000
Total principal outstanding		177,500,000	177,500,000
Unamortized debt discount		(548,000)	(548,000)
Unamortized debt issuance costs		(473,000)	(473,000)
Finance lease liabilities		618,000	618,000
Total		177,097,000	177,097,000
Less: current portion		(10,356,000)	(10,356,000)
Total long-term debt, net and other borrowings		$ 166,741,000	166,741,000		$ 197,699,000
Gain on extinguishment of debt			$ 889,000	$ 0
Royalty-Backed Loan
Debt Instrument [Line Items]
Debt instrument face amount	$ 50,000,000
Extinguishment of debt	30,900,000
Prepayment of debt	500,000
Gain on extinguishment of debt	$ 900,000
2019 Term Loan Facility
Debt Instrument [Line Items]
Debt instrument term		5 years
Interest rate		2.10%	2.10%

Derivative Instruments (Detail)

Derivative Instruments (Detail) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Mar. 31, 2020
Derivative [Line Items]
Pre-tax deferred losses expected to be reclassified to earnings during the next 12 months	$ 700,000
Cash Flow Hedge | Interest Rate Swaps
Derivative [Line Items]
Notional amount			$ 100,000,000
Average fixed interest rate			0.82%
Cash Flow Hedge | Interest Rate Swaps | Accrued expenses and other liabilities
Derivative [Line Items]
Liabilities	$ 766,000	$ 1,908,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, tax	$ 200	$ 500
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	514,205	114,601
Other comprehensive income (loss) before reclassifications	367	(1,793)
Amounts reclassified to earnings	539	243
Ending balance	499,344	513,579
Foreign currency translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(630)	(960)
Other comprehensive income (loss) before reclassifications	55	(9)
Amounts reclassified to earnings	0	0
Ending balance	(575)	(969)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(1,418)	0
Other comprehensive income (loss) before reclassifications	312	(1,784)
Amounts reclassified to earnings	539	243
Ending balance	(567)	(1,541)
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,048)	(960)
Ending balance	$ (1,142)	$ (2,510)

Stock-Based Compensation (Detai

Stock-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 3,867	$ 3,992	$ 11,772	$ 10,452
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	144	864	1,672	2,127
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	684	621	1,726	1,268
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,330	1,926	6,641	5,735
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 709	$ 581	$ 1,733	$ 1,322

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (13,415)	$ (6,386)	$ (31,064)	$ (10,061)
Basic weighted-average common shares outstanding (in shares)	67,623	66,820	67,409	49,858
Basic loss per common share (in dollars per share)	$ (0.20)	$ (0.10)	$ (0.46)	$ (0.20)
Diluted loss per common share (in dollars per share)	$ (0.20)	$ (0.10)	$ (0.46)	$ (0.20)
Antidilutive securities excluded from diluted net income per common share (in shares)	3,051	2,588	3,051	1,657

Other Loss (Income) (Details)

Other Loss (Income) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Income and Expenses [Abstract]
Foreign currency losses (gains)	$ 127	$ (33)	$ 156	$ 187
Tax indemnification loss (income), net	3,823	(555)	3,092	(1,664)
Interest income	(11)	(7)	(39)	(221)
Other	1	(1)	0	(4)
Total other loss (income)	$ 3,940	$ (596)	$ 3,209	$ (1,702)

Commitments and Contingencies (

Commitments and Contingencies (Details)	1 Months Ended
	Oct. 31, 2015patent	Feb. 27, 2019EUR (€)
European
Loss Contingencies [Line Items]
Number of patents | patent	3
MIP
Loss Contingencies [Line Items]
Court deposit | €		€ 400,000

Segment Information (Details)

Segment Information (Details)	9 Months Ended
	Sep. 30, 2021segment
Segment Reporting [Abstract]
Operating segments	1

Leases - Operating and Finance

Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Operating	$ 8,287	$ 18,441
Finance	508	525
Total leased assets	8,795	18,966
Current liabilities
Operating	1,397	1,164
Finance	356	249
Noncurrent
Operating	16,391	17,501
Finance	262	246
Total leased liabilities	$ 18,406	$ 19,160
Operating lease, right-of-use asset, statement of financial position [Extensible Enumeration]	Other long-term assets	Other long-term assets
Finance lease, right-of-use asset, statement of financial position [Extensible Enumeration]	Property, plant and equipment, net	Property, plant and equipment, net
Operating lease, liability, current, statement of financial position [Extensible Enumeration]	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Finance lease, liability, current, statement of financial position [Extensible Enumeration]	Current portion of long-term debt and other borrowings	Current portion of long-term debt and other borrowings
Operating lease, liability, noncurrent, statement of financial position [Extensible Enumeration]	Other long-term liabilities	Other long-term liabilities
Finance lease, liability, noncurrent, statement of financial position [Extensible Enumeration]	Long-term debt, net and other borrowings	Long-term debt, net and other borrowings

Leases (Details)

Leases (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Leases [Abstract]
Impairment, lessor asset under operating lease	$ 9.5	$ 9.5